DK0935469T3 - Anvendelse af væksthormon - Google Patents

Anvendelse af væksthormon

Info

Publication number
DK0935469T3
DK0935469T3 DK97919856T DK97919856T DK0935469T3 DK 0935469 T3 DK0935469 T3 DK 0935469T3 DK 97919856 T DK97919856 T DK 97919856T DK 97919856 T DK97919856 T DK 97919856T DK 0935469 T3 DK0935469 T3 DK 0935469T3
Authority
DK
Denmark
Prior art keywords
growth hormone
medicament
treatment
individuals
metabolic
Prior art date
Application number
DK97919856T
Other languages
Danish (da)
English (en)
Inventor
Per Marin
Lars Loenn
Malin Ottosson
Kaj Stenlof
Per Bjoerntorp
Lars Sjoestroem
Bengt-Ake Bengtsson
Gudmundur Johannsson
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Application granted granted Critical
Publication of DK0935469T3 publication Critical patent/DK0935469T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Steroid Compounds (AREA)
DK97919856T 1996-04-12 1997-04-10 Anvendelse af væksthormon DK0935469T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9601397A SE9601397D0 (sv) 1996-04-12 1996-04-12 Use of growth hormone
PCT/SE1997/000601 WO1997038709A1 (en) 1996-04-12 1997-04-10 Use of growth hormone

Publications (1)

Publication Number Publication Date
DK0935469T3 true DK0935469T3 (da) 2003-03-17

Family

ID=20402176

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97919856T DK0935469T3 (da) 1996-04-12 1997-04-10 Anvendelse af væksthormon

Country Status (11)

Country Link
EP (1) EP0935469B1 (de)
JP (1) JP2000510451A (de)
AT (1) ATE228007T1 (de)
CA (1) CA2250907A1 (de)
DE (1) DE69717301T2 (de)
DK (1) DK0935469T3 (de)
ES (1) ES2187771T3 (de)
NZ (1) NZ332105A (de)
PT (1) PT935469E (de)
SE (1) SE9601397D0 (de)
WO (1) WO1997038709A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087090A (en) * 1997-02-25 2000-07-11 Celtrix Pharmaceuticals, Inc. Methods for predicting drug response
DE69803298T2 (de) * 1997-07-04 2002-08-08 Pharmacia Ab Verwendung des wachstumshormons in mitteln zur behandlung der insulinresistenz im herzen
CA2352316A1 (en) 1998-11-26 2000-06-02 Auckland Uniservices Limited Treatment of hypertension
TW514510B (en) 1999-06-11 2002-12-21 Tanita Seisakusho Kk Method and apparatus for measuring distribution of body fat
AU1130501A (en) * 1999-11-03 2001-05-14 Novo Nordisk A/S Use of a growth hormone or a growth hormone secretagogue for appetite-suppression or induction of satiety
AU2006200127B2 (en) * 2000-03-13 2007-10-25 Pfizer Inc. Use of growth hormone in low dose
SE0000837D0 (sv) * 2000-03-13 2000-03-13 Pharmacia & Upjohn Ab New use
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
US20040248788A1 (en) * 2001-07-06 2004-12-09 Vickers Mark Hedley Hypertenson treatment
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005020898A2 (en) 2003-08-21 2005-03-10 Tercica, Inc. Methods of reducing visceral fat by increasing levels of insulin-like growth factor-i (igf-i)
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
JP2010518090A (ja) 2007-02-09 2010-05-27 トランザイム・ファーマ，インコーポレイテッド 大環状グレリン受容体修飾因子およびその使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268277A (en) * 1987-08-07 1993-12-07 Eniricerche S.P.A. Method for the preparation of human growth hormone

Also Published As

Publication number Publication date
DE69717301T2 (de) 2003-09-04
CA2250907A1 (en) 1997-10-23
EP0935469A1 (de) 1999-08-18
NZ332105A (en) 2000-03-27
EP0935469B1 (de) 2002-11-20
SE9601397D0 (sv) 1996-04-12
JP2000510451A (ja) 2000-08-15
WO1997038709A1 (en) 1997-10-23
ES2187771T3 (es) 2003-06-16
PT935469E (pt) 2003-03-31
DE69717301D1 (de) 2003-01-02
ATE228007T1 (de) 2002-12-15

Similar Documents

Publication Publication Date Title
DK0935469T3 (da) Anvendelse af væksthormon
Blair et al. Sustained compression and healing of chronic venous ulcers.
Poirier et al. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients
DE69809558T2 (de) Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2
HUP0100391A2 (hu) Monomer inzulinanalógokat tartalmazó gyógyászati készítmény és alkalmazása
UA83854C2 (uk) Застосування телмісартану для підвищення чутливості до інсуліну
EP0766966A3 (de) Methode zur Behandlung der Insulinresistenz
McGregor The free radial forearm flap—the management of the secondary defect
US7169121B2 (en) Elastic dynamic immobilizer for fingers or toes
NO940180D0 (no) Anvendelse av IGF-I
WO2002070546A3 (en) Modified derivatives of cck-8
Ampudia-Blasco et al. A new case of lipoatrophy with lispro insulin in insulin pump therapy: is there any insulin preparation free of complications?
ES2181923T3 (es) 4-hidroxicumarin-3-carboxamidas para el tratamiento de la diabet es mellitus no dependiente de la insulina.
Gupta et al. Volar compartment syndrome of the arm complicating a fracture of the humeral shaft: A case report
ES2166406T3 (es) Uso de derivados de 1,5-benzodiazepina para el control del vaciado gastrico en pacientes con diabetes mellitus no dependiente de insulina.
EA200600757A1 (ru) Тетрапептид, регулирующий уровень глюкозы в крови при сахарном диабете
ES2168772T3 (es) Uso de hormona del crecimiento en composiciones para el tratamiento de la resistencia del corazon a la insulina.
Pick et al. The epidemiology of hypertension family practice in Cape Town
Tibrewal et al. Is day surgery for Wilson's osteotomy safe?
Holst et al. Diurnal profile of pancreatic polypeptide and gut glucagon in human morbid obesity
RU96115219A (ru) Способ лечения больных сахарным диабетом
BR0309375A (pt) Tratamento de sìndrome metabólica
HK1070594A1 (en) Treatment of type i diabetes mellitus using growthhormone antagonists
Marris TAHYCARDIA: OBSERVATIONS UPON ITS OCCURRENCE IN THE ENTERIC AND OTHER FEVERS
Percy Tendon lacerations of the hand.(Case P41).